Enanta Pharmaceuticals, Inc. (ENTA), a clinical-stage biotechnology company, Monday announced positive topline results from the Phase 2 study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV). The company's shares were up more than 4 percent in pre-market.
Results from the study, which was conducted in two parts in pediatric patients with RSV aged 28 days to 36 months, showed that zelicapavir demonstrated a viral load decline of 1.2 log compared to placebo at day 5. Additionally, Zelicapavir was well-tolerated with a favorable safety profile.
Enanta stock had closed at $8.00, down 0.12 percent on Friday. It has traded in the range of $7.86 - $17.80 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.